A phase I trial of neratinib (an irreversible pan-HER inhibitor) and temsirolimus (mTOR inhibitor) suggested benefit in five patients with HER2-mutant NSCLC (19). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.